股腘动脉TASC II D病变:腔内治疗与旁路手术的单中心比较
旁路组6、12、24个月一期通畅率均优于腔内组,24个月再干预率更低,肢体挽救率无差异。
要点
- 股腘动脉TASC II D病变中,旁路组6、12、24个月一期通畅率均显著优于PTA±BMS组。
- 旁路组24个月再干预率20%,显著低于腔内组的45%。
- 两组24个月肢体挽救率无显著差异,CLI和流出道差是再狭窄/闭塞及再干预的独立危险因素。
核心结论
- 对于股腘动脉TASC II D严重闭塞病变,Propaten-Gore旁路+Linton补片安全有效,早中期再狭窄/闭塞和再干预率似乎优于PTA±BMS。
- 需要更大样本和更长随访来进一步明确该优势。
研究设计与样本
- 组A接受PTA±BMS,组B接受Propaten-Gore旁路+Linton补片,随访采用临床评估和多普勒超声。
主要发现
- 组A与组B平均闭塞长度分别为22.1 cm(范围8-37)和25.2 cm(范围9-41),P=ns。
- 平均手术时间组A为83.5分钟,组B为114分钟,P=0.02。
- 平均随访26.7个月(范围3-46)。
- 6、12、24个月一期通畅率组A vs 组B分别为76.9% vs 97.5%(P=0.007)、65.7% vs 89.1%(P=0.05)、52.6% vs 78.1%(P=0.005)。
- 24个月再干预率组A为45%,组B为20%(P=0.03);24个月肢体挽救率组A为90%,组B为92.5%(P=ns)。
关键数值与推荐
- 6、12、24个月辅助一期通畅率组A vs 组B分别为76.9% vs 97.5%(P=0.007)、68.5% vs 91.8%(P=0.02)、57.8% vs 87.5%(P=0.001)。
- 6、12、24个月二期通畅率组A vs 组B分别为94.8% vs 97.5%(P=ns)、85.7% vs 97.2%(P=ns)、73.6% vs 93.7%(P=0.004)。
- 单因素分析显示CLI和流出道差是靶动脉显著再狭窄/闭塞及再干预的独立危险因素。
临床怎么用
- 对于股腘动脉TASC II D病变,旁路手术(Propaten-Gore+Linton补片)可作为安全有效的血运重建选择。
- 腔内治疗(PTA±BMS)再狭窄/闭塞和再干预率较高,选择时应考虑病变长度和流出道情况。
局限性
- 随访时间有限(平均26.7个月),需要更大样本和更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with severe occlusive disease (Trans-Atlantic Inter-Society Consensus II D [TASC II D]) of the femoropopliteal segment, the advantages of endovascular versus bypass revascularization still remain debated. Most reports available in literature comparing percutaneous transluminal angioplasty (PTA) ± bare metal stent (BMS) versus synthetic bypass analyze patients with heterogeneous anatomical lesions creating possible bias when results of different treatments are matched. In this study, we compared early and midterm outcomes of PTA ± BMS versus heparin-bonded expanded polytetrafluoroethylene graft (Propaten-Gore) + Linton patch in patient affected by symptomatic femoropopliteal TASC II-D lesions. METHODS: Eighty limbs with symptomatic severe occlusive disease (TASC II D) of the femoropopliteal segment observed from January 2013 to January 2017 were included in this retrospective study. Indication to treatment was severe claudication in 17 limbs (21.2%) and critical limb ischemia (CLI) in 63 (78.8%). 36.2% of limbs presented at least 2 distal patent vessels, and 63.8% had only 1 patent vessel. Of these limbs, 40 were treated by means of PTA ± BMS (group A), and 40 were treated by means of femoropopliteal bypass with Propaten-Gore graft + Linton patch (group B). Patients were followed with a clinical assessment and duplex at 1, 6, and 12 months after procedure and then annually. A closer follow-up was performed in case of any complication. Patency, reintervention rate, and limb salvage were compared in the 2 groups. RESULTS: The mean length of arterial occlusion was 22.1 cm (range, 8-37) in group A versus 25.2 cm (range, 9-41) in group B, P = ns. A slight difference in mean procedural time was observed (83.5 min of group A versus 114 min of group B, minutes, P = 0.02). Mean follow-up was 26.7 months (range, 3-46). Primary patency at 6, 12, and 24 months of group A versus group B was 76.9% vs. 97.5% (P = 0.007), 65.7% vs. 89.1% (P = 0.05), and 52.6% vs. 78.1% (P = 0.005), respectively. Assisted primary patency was 76.9% vs. 97.5% (P = 0.007), 68.5% vs. 91.8% (P = 0.02), and 57.8% vs. 87.5% (P = 0.001), respectively. Secondary patency was 94.8% vs. 97.5% (P = ns), 85.7% vs. 97.2% (P = ns), 73.6% vs. 93.7% (P = 0.004), respectively. Rate of reintervention at 24 months was 45% in group A vs. 20% in group B (P = 0.03). Limb salvage rate at 24 months was 90% for group A vs. 92.5% for group B (P = ns). Univariate analysis showed CLI and poor runoff to be independent risk factors for significant restenosis/occlusion of target artery and reintervention. CONCLUSIONS: In patients with severe femoropopliteal occlusive disease (TASC II D), the surgical revascularization by means of Propaten-Gore bypass + Linton patch can be considered safe and effective. Early and midterm results of this approach seem to be superior to PTA ± BMS in terms of restenosis/occlusion and reintervention rates. Larger cohort and longer term results are mandatory to better define this advantage.
引用
- Veraldi GF, Mezzetto L, Macrì M, et al. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study. Ann Vasc Surg. 2017. PMID: 28943491. doi:10.1016/j.avsg.2017.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。